Candel Therapeutics to present NSCLC aglatimagene besadenovec study data at SITC 2026

• Candel Therapeutics set two poster presentations at SITC’s 41st Annual Meeting, November 4-8, 2026 in Phoenix.
• Results will be presented in the future, not previously disclosed in this announcement.
• NSCLC poster highlights analyses linking aglatimagene besadenovec with immune activation tied to improved survival after checkpoint inhibitor failure.
• Recurrent glioblastoma poster outlines phase 1b findings supporting linoserpaturev combined with VEGF blockade to counter tumor-driven immune suppression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900PRIMZONEFULLFEED9838084) on October 02, 2026, and is solely responsible for the information contained therein.